The Parkinson's Disease Therapeutics Conference (PDTC) is The Michael J. Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development. The 16th Annual PD Therapeutics Conference is scheduled to be held on October 17, 2024, in New York City.
Each year, the PD Therapeutics Conference brings together 300 research and business development professionals from both academia and industry and showcases the most exciting and innovative research from MJFF's research portfolio. Novel advances in basic and translational research from both academic and industry labs are highlighted through speaker presentations and a poster session. The event is a platform for field leaders to share new and unpublished results and for fostering new relationships and collaborations.
Thank you for your enthusiasm and interest in this year's conference. Due to overwhelming demand, we have reached full capacity. Registration is now officially closed and unfortunately onsite registration will not be available.
-
Bruce Morimoto, PhD
Vice President, Drug Development | Alto Neuroscience
Bruce Morimoto, PhD, has spent his career leading project teams in developing innovative medicines for neurodegenerative diseases like PD, AD, ALS and FTD. His responsibilities have encompassed a broad range of drug development activities including manufacturing, nonclinical safety testing, regulatory affairs and translational clinical research. Morimoto held leadership roles at Allon Therapeutics, Celerion, Alkahest, and Cerecin. He is on the advisor boards of several biotech companies helping to develop and deploy scientific, regulatory and medical strategy. Morimoto started his career on the faculty in the Chemistry Department at Purdue University. He earned his doctorate in biochemistry from the University of California, Los Angeles (UCLA) under the mentorship of Daniel E. Atkinson, and completed post doctorate training at University of California, Berkeley with Daniel Koshland Jr.
-
Mark Frasier, PhD
Chief Scientist | The Michael J. Fox Foundation for Parkinson's Research
Mark Frasier, PhD, joined The Michael J. Fox Foundation (MJFF) in 2006. As Chief Scientist, Frasier regularly meets with academic and industry researchers around the world to identify promising proposals to support, providing troubleshooting and ongoing management of projects as they go forward. He also supports the Foundation's priority interest in developing biomarkers for Parkinson's disease that will accelerate clinical trials of new drugs. Frasier earned an undergraduate degree in Biochemistry from the University of Dayton and a PhD in Pharmacology from Loyola University Chicago. He completed his postdoctoral work in the Neuroscience Discovery Research Group at Eli Lilly, Inc., in Indianapolis, Indiana, where he worked on drug-discovery research in Parkinson's and Alzheimer's disease. In addition to his work as a Foundation scientist, Frasier is a Team Fox member, running the New York ING Marathon and playing golf to raise critical funds for research.
-
Tanya Simuni, MD
Professor of Neurology, Director, Parkinson's Disease and Movement Disorders Center| Northwestern University Feinberg School of Medicine
Tanya Simuni, MD, joined the faculty of the Northwestern University Feinberg School of Medicine in 2000 to build a multidisciplinary movement disorders center that is recognized by the Parkinson’s Foundation, Huntington Disease Society of America and Wilson’s Foundation as a Center of Excellence and serves as a training model in the region. She is the lead investigator of a number of clinical trials on experimental pharmacology, non-motor manifestations, and pharmacological management of PD. She serves on a number of Steering Committees for the PD national clinical trials, several committees for PSG and the PF. She is the Site PI and Steering Committee member for the largest PD biomarker initiative (PPMI study) and site PI for the Network for Excellence in Neuroscience Clinical Trials (NEXT). Simuni is an active member of the American Academy of Neurology, American Neurological Association, the Movement Disorders Society as well as the Parkinson’s Study Group.
-
Poster Presentations
Understanding Diversity in a Global Parkinson's Disease Cohort
Maggie Kuhl | The Michael J. Fox Foundation
The Aligning Science Across Parkinson’s Initiative: Changing the Way Science is Done to Accelerate Discoveries in Parkinson’s Disease Research
Ekemini Riley, PhD | Aligning Science Across Parkinson's
Sonya Dumanis, PhD | Aligning Science Across Parkinson's
Neuron-derived Extracellular Vesicles from Human Blood for Alpha-synuclein Assessment in Diverse Synucleinopathies
Erez Eitan, PhD | Neurodex
Optimization of MDS-UPDRS for Use in Early-stage Parkinson’s Disease Clinical Trials
Diane Stephenson, PhD | Critical Path Institute
Thomas Morel, PhD | UCB
Integrated, Collaborative, Multimodal Data Approach in Parkinson’s Disease
John Seaman, PhD | Novartis
Targets to Therapies: A New Target De-Risking Initiative at MJFF
Darryle Schoepp, PhD | Independent Consultant
Steven Braithwaite, PhD | Bayshore Global Management
Virginie Buggia-Prevot, PhD | Valo Health
Advanced Quantification and Standardization of Dopaminergic Imaging Markers with the Centamine Scale
Roger Gunn, PhD | XingImaging
The 16th annual Parkinson's Disease Therapeutics Conference is made possible by the generous support of our sponsors.
Gold Sponsors:
Mitsubishi Tanabe Pharma America | NeuroDerm
UCB Pharmaceuticals | Novartis
Interested in Sponsorship Opportunities?
View our sponsorship opportunities menu to support this year's conference.
Interested in learning more? Get in touch: researchpartnerships@michaeljfox.org.
-
2023 Conference
-
2022 Conference
-
2020-2021 Webinars
-
2019 Conference
-
2018 Conference
-
2017 Conference
-
2016 Conference
-
2015 Conference
-
2014 Conference
-
2013 Conference
-
2012 Conference
-
2011 Conference
-
2010 Conference
-
2009 Conference